Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2009-06-09
2010-02-23
Saunders, David A (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S001690, C424S136100, C424S155100, C424S156100
Reexamination Certificate
active
07666415
ABSTRACT:
The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a targetable conjugate. The targetable conjugate encompasses a hapten to which antibodies have been prepared. In preferred embodiments, the hapten is histamine-succinyl-glycine (HSG). In more preferred embodiments, the at least one arm comprises the CDR sequences of the HSG-binding 679 antibody. The targetable conjugate is attached to one or more therapeutic and/or diagnostic agents. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them and kits comprising them.
REFERENCES:
patent: 4468457 (1984-08-01), Goldenberg et al.
patent: 4735210 (1988-04-01), Goldenberg
patent: 4737453 (1988-04-01), Primus
patent: 4792521 (1988-12-01), Shochat
patent: 4818709 (1989-04-01), Primus et al.
patent: 4863713 (1989-09-01), Goodwin et al.
patent: 4971792 (1990-11-01), Steplewski et al.
patent: 5078998 (1992-01-01), Bevan et al.
patent: 5101827 (1992-04-01), Goldenberg
patent: 5128119 (1992-07-01), Griffiths
patent: 5183756 (1993-02-01), Schlom
patent: 5225541 (1993-07-01), Hackett et al.
patent: 5274076 (1993-12-01), Barbet et al.
patent: 5328679 (1994-07-01), Hansen et al.
patent: 5469854 (1995-11-01), Unger et al.
patent: 5502037 (1996-03-01), Kondratyev
patent: 5503987 (1996-04-01), Wagner et al.
patent: 5534254 (1996-07-01), Huston
patent: 5534326 (1996-07-01), Trokhan et al.
patent: 5591828 (1997-01-01), Bosslet et al.
patent: 5683694 (1997-11-01), Bagshawe et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5697902 (1997-12-01), Goldenberg
patent: 5716595 (1998-02-01), Goldenberg
patent: 5746996 (1998-05-01), Govindan et al.
patent: 5753206 (1998-05-01), McBride et al.
patent: 5772981 (1998-06-01), Govindan et al.
patent: 5776093 (1998-07-01), Goldenberg
patent: 5776094 (1998-07-01), Goldenberg
patent: 5776095 (1998-07-01), Goldenberg
patent: 5837242 (1998-11-01), Holliger et al.
patent: 5837243 (1998-11-01), Deo et al.
patent: 5851527 (1998-12-01), Hansen
patent: 5959083 (1999-09-01), Bosslet et al.
patent: 6010680 (2000-01-01), Govindan et al.
patent: 6077499 (2000-06-01), Griffiths et al.
patent: 6096289 (2000-08-01), Goldenberg
patent: 6121424 (2000-09-01), Whitlow et al.
patent: 6126916 (2000-10-01), McBride et al.
patent: 6187284 (2001-02-01), Griffiths
patent: 6540980 (2003-04-01), Blumenthal et al.
patent: 6962702 (2005-11-01), Hansen et al.
patent: 7074405 (2006-07-01), Hansen et al.
patent: 7138103 (2006-11-01), Goldenberg et al.
patent: 7429381 (2008-09-01), Hansen et al.
patent: 0263046 (1988-04-01), None
patent: 0419387 (1991-03-01), None
patent: 0511011 (1992-10-01), None
patent: 0517024 (1992-12-01), None
patent: 0623675 (1994-11-01), None
patent: 921782 (1992-12-01), None
patent: 9604313 (1996-02-01), None
patent: 9808875 (1998-03-01), None
patent: 9966951 (1999-12-01), None
patent: 0034317 (2000-06-01), None
ALT et al. “Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin gamma1 Fc or CH3 region” FEBS Lett. Jul. 2, 1999, 454(1-2):90-4.
Arano et al. “Reassessment of Diethylenetriaminepentaacetic Acid (DTPA) as a Chelating Agent for Indium-111 Labeling of Polypeptides Using a Newly Synthesized Monoreactive DTPA Derivative” J. Med. Chem. 1996, 39, 3451-3460.
Bamias and Epenetos “Two-Step Strategies for the Diagnosis and Treatment of Cancer with Bioconjugates” Antibody, Immunoconj. Radiopharm., 5(4):385-395, 1992.
Barbet et al. “Radioimmunotherapy of LS174T Colon Carcinoma in Nude Mice Using an lodine-131-Labeled Bivalent Hapten Combined with an Anti-CEA x Anti-Indium-DTPA Bispecific Antibody” Tumor Biology, 18 (Suppl. 2), p. 31 (1997).
Barbet et al. “Radioimmundetection of medullary thyroid carcinoma using Indium-111 bivalent hapten and Anti-CEA x Anti-DTPA-Indium bispecific antibody” J. Nucl. Med. Jul. 1998; 39(7):1172-8.
Bardies et al. “Bispecific antibody and lodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer” J. Nucl. Med. Nov. 1996; 37(11):1853-9.
Boden et al. “Preliminary Study of the Metal Binding Site of an Anti-DTPA-Indium Antibody by Equilibrium Binding Immunoassays and Immobilized Metal Ion Affinity Chromatography” Bioconjugate Chem. 1995, 6, 373-379.
Bos et al. “In Vitro Evaluation of DNA-DNA Hybridization as a Two-Step Approach in Radioimmunotherapy of Cancer” Cancer Res. 54, 3479-3486, Jul. 1, 1994.
Bosslet et al. “Generation of Bispecific Monoclonal Antibodies for Two Phase Radioimmunotherapy” Br. J. Cancer May 1991; 63(5):681-6.
Chatziioannou et al. “MICROPET I: Performance Evaluation of a Very High Resolution PET Scanner for Imaging Small Animals” J. Nucl. Med. 38(5), May 1997 Suppl., No. 19, p. 7P-8P.
De Boisferon et al. “Enhanced Targeting Specificity to Tumor Cells by Simultaneous Recognition of Two Antigens” Bioconj. Chem. 2000, 11, 452-460.
De Jonge et al. Production and Characterization of Bispecific Single-Chain Antibody Fragments Mol. Immunol. 32 (17/18):1405-1412 (1995).
Dubel et al. “Reconstitution of human pancreatic RNase from two separate fragments fused to different single chain antibody fragments: On the way to binary immunotoxins” Tumor Targeting (1999) 4, 37-46.
Gautherot et al. “Radioimmunotherapy of LS174T Colon Carcinoma in Nude Mice Using an lodine-131-Labeled Bivalent Hapten Combined with an Anti-CEA x Anti-lndium-DTPA Bispecific Antibody” J. Nucl. Med. 38(5), May 1997 Suppl., No. 18, p. 7P.
Gautherot et al. “Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens” J. Nucl. Med. Nov. 1998; 39(11):1937-43.
Gautherot et al. “Therapy for colon carcinoma xenografts with bispecific antibody-targeted, iodine-131-labeled bivalent hapten” Cancer Dec. 15, 1997; 80(12 Suppl.):2618-23.
Gold et al. “Murine Monoclonal Antibodies to Colon-specific Antigen p1” Cancer Res. 50, 6405-6409, Oct. 1, 1990.
Goodwin et al. “Pre-targeted immunoscintigraphy of murine tumors with Indium-111-labeled bifunctional haptens” J. Nucl. Med. Feb. 1988; 29(2):226-34.
Greenwood et al. “The Preparation of 131I-Labelled Human Growth Hormone of High Specific Radioactivity” Biochem. J. (1963) 89, 114-123.
Hayden et al. “Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system” Therapeutic Immunology 1994, 1, 3-15.
Hawkins et al. “Delivery of radionuclides to pretargeted monoclonal antibodies using dihydrofolate reductase and methotrexate in an affinity system” Cancer Res. May 15, 1993; 53(10 Suppl.):2368-73.
Hosono et al. “Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and lodine-125-labeled bivalent hapten” J. Nucl. Med. Sep. 1993; 39(9):1608-13.
Kaneko et al. “New Hydrazone Derivatives of Adriamycin and Their Immunoconjugates-a Correlation between Acid Stability and Cytotoxicity” Bioconj. Chem. 2(3):133-141 (1991).
Karacay et al. “Studies on a humanized anti-CEA x murine anti-(In-DTPA) bispecific antibody construct for radioimmunotherapy of CEA-positive tumors” Proc. Natl. Acad. Sci. USA, vol. 40, p. 644, Mar. 1999.
Karacay et al. “Experimental Pretargeting Studies of Cancer with a Humanized anti-CEA x Murine anti-[IN-DTPA] Bispecific Antibody Constructs and a 99mTc-/188Re-Labeled Peptide” Bioconj. Chem. 2000, 11, 842-854.
Karacay et al. “Pretargeting Studies with a Murine Anti-Colon-Specific Antigen-P (CSAp) x Chimeric Anti-[lndium-DTPA] Bispecific Antibody and Technetium-99m-Labeled Peptide” Cancer Biother. Radiopharm. 15(4):412 (200
Griffiths Gary L.
Hansen Hans J.
Leung Shui-on
McBride William J.
Qu Zhengxing
Immunomedics Inc.
Nakashima Richard A.
Saunders David A
LandOfFree
Production and use of novel peptide-based agents for use... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Production and use of novel peptide-based agents for use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Production and use of novel peptide-based agents for use... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4153542